Scholar Rock Holding Corporation
SRRK
Classifica tra le azioni
#3482
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Prezzo delle azioni
$40.54
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$4.94B
Variazione (1 giorno)
1.59%
Variazione (1 anno)
45.19%
Paese
US
Scambia Scholar Rock Holding Corporation (SRRK)
Categoria
Healthcare
Storico del rendimento da dividendi per Scholar Rock Holding Corporation (SRRK)
Il rendimento da dividendi (TTM) di Scholar Rock Holding Corporation (simbolo azionario: SRRK) al 2023-12-31 è: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Scholar Rock Holding Corporation (SRRK) da 2016 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
| Anno | Rendimento da dividendi | Cambia |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
| Azienda | Rendimento da dividendi | Il paese |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
